Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.59 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.59 |
| ▸ | REN | P00797 | 1/20 | 0.59 |
| ▸ | CTSD | P07339 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782416 | 0.92 | BACE1 (0.57) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4109037 | 0.89 | BACE1 (0.76) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4228426 | 0.88 | BACE1 (0.69) | BACE1BACE2APPRENCTSD | |
| SCHEMBL27749223 | 0.86 | BACE1 (0.59) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4304428 | 0.85 | BACE1 (0.74) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4238411 | 0.85 | BACE1 (0.76) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4102220 | 0.85 | BACE1 (0.76) | BACE1BACE2APPRENCTSD | |
| SCHEMBL5135046 | 0.84 | BACE1 (0.60) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4234214 | 0.84 | BACE1 (0.79) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4227218 | 0.84 | BACE1 (0.79) | BACE1BACE2APPRENCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161269-A1 | Compounds 620 | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| US-20080161269-A1 | Compounds 620 | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| WO-2008076045-A1 | NOVEL 2-AMINO- 5-ARYL-IMIDAZOL-4 -ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161269-A1 | Compounds 620 | MAPT, PSEN1, PSEN2 | BACE1 4/4885BACE2 29/4885APP 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.